Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial

Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105, Silwinska-Stanczyk, P et al. (11 more authors) (2021) Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Metadata

Authors/Creators:
Dates:
  • Published: September 2021
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 05 Aug 2022 11:55
Last Modified: 05 Aug 2022 11:55
Status: Published
Identification Number: https://doi.org/10.1002/art.41966
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)